Recent Updates
Recently added Catalysts
BTAI Negative Sentiment Score: 15/100

BioXcel Therapeutics, Inc: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline

Key Takeaway: BioXcel Therapeutics, Inc. is facing a class-action lawsuit brought by the Portnoy Law Firm on behalf of investors who purchased its securities between December 15, 2021, and June 28, 2023. The lawsuit claims that the company made false and misleading statements regarding its business operations and failed to disclose significant issues affecting its regulatory processes. These alleged failures include inadequate internal controls and compliance issues related to informed consent and data integrity, negatively impacting its ability to secure FDA approval for its product. Investors are encouraged to contact the law firm for further legal options.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges material misrepresentation and omissions by the company.
  • Claims that the internal controls concerning protocols and data integrity were inadequate.
  • Issues with compliance of the principal investigator with regulatory standards.
  • Allegations of fabricated correspondence submitted to the FDA.

Full Press Release Details

LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”).
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The lawsuit filed in this class action asserts that during the designated period, the Defendants made statements that were materially false and/or deceptive, and also neglected to disclose crucial negative information about the Company's business, operations, and future prospects. Specifically, the Defendants failed to inform investors of the following: (1) the Company's inadequate internal controls concerning adherence to protocols and data integrity; (2) the failure of the Company's principal investigator to comply with the approved informed consent form from the Institutional Review Board; (3) the inadequate maintenance of complete case histories for certain patients whose records were reviewed by the FDA; (4) the fabrication of email correspondence between the Company's principal investigator and a pharmacovigilance safety vendor, which was then submitted to the FDA; (5) the detrimental impact of these issues on the Company's ability to obtain regulatory approval for BXCL501 as a treatment for agitation associated with dementia in probable Alzheimer's disease patients; and (6) as a result of the aforementioned issues, the Defendants' positive statements about the Company's business, operations, and prospects were significantly misleading and lacked a reasonable basis.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

What is the lawsuit about BioXcel Therapeutics?

The lawsuit alleges that BioXcel made false statements and failed to disclose vital issues affecting its business.

Who filed the lawsuit against BioXcel?

The lawsuit was filed on behalf of investors by The Portnoy Law Firm.

What is the class period for the BioXcel lawsuit?

The class period for the lawsuit is from December 15, 2021 to June 28, 2023.

How can investors contact The Portnoy Law Firm?

Investors can reach out to attorney Lesley F. Portnoy at 844-767-8529 or via email.

What issues are highlighted in the lawsuit?

The lawsuit points out inadequate internal controls and failure to comply with regulations among others.

Last updated: Jul 12, 2023